What is Ilumya?
Ilumya (also known by its generic name tildrakizumab-asmn) was approved by the FDA in March 2018 for the treatment of moderate-to-severe plaque psoriasis in adults.
Ilumya is given by injection under the skin at weeks 0, 4, and every 12 weeks thereafter.
To learn more, please visit the Ilumya website.
Clinical trial data show drug may help achieve clear skin.
The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.
